共 167 条
[21]
Reynolds KL(2003)A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 320-327
[22]
Gadd MA(2007)Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J. Clin. Oncol. 25 4414-4422
[23]
Ellisen LW(2017)Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) J. Clin. Oncol. 35 1061-1069
[24]
Isakoff SJ(2016)Palbociclib and letrozole in advanced breast cancer N. Engl. J. Med 375 1925-1936
[25]
Ellis MJ(2016)Ribociclib as first-line therapy for hr-positive, advanced breast cancer N. Engl. J. Med 375 1738-1748
[26]
Tao Y(2017)MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer J. Clin. Oncol. 35 3638-3646
[27]
Luo J(2017)NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer Clin. Cancer Res 23 4055-4065
[28]
A’Hern R(2018)Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer Ann. Oncol. 29 2334-2340
[29]
Evans DB(undefined)undefined undefined undefined undefined-undefined
[30]
Bhatnagar AS(undefined)undefined undefined undefined undefined-undefined